INTRODUCTION {#s1}
============

Skeletal muscles comprise approximately 50% of the body weight and account for \~80% of insulin-stimulated glucose uptake \[[@R1], [@R2]\], therefore playing critical roles in whole-body energy balance and glucose homeostasis \[[@R3]\]. High-fat diet-induced obesity often causes insulin resistance \[[@R4], [@R5]\], which is associated with decreased mitochondrial oxidative capacity and ATP synthesis in the skeletal muscle \[[@R6]-[@R9]\]. Conversely, improved skeletal muscle mitochondrial function contributes to enhanced fatty acids β-oxidation and higher insulin sensitivity \[[@R10]-[@R12]\]. Therefore, mitochondrial function in skeletal muscle serves as a target for the treatment of high-fat diet-induced obesity and insulin resistance.

Butyrate is a short-chain fatty acid produced from anaerobic bacteria fermentation of dietary fibers in the colon \[[@R13]\]. Butyrate functions not only as a nutrient, but also as a signal to regulate various cellular activities \[[@R14]\]. Firstly, butyrate acts as a histone deacetylase (HDAC) inhibitor to participate in the epigenetic gene regulation \[[@R15]\]; Secondly, butyrate can activate its G protein-coupled receptors, GPR41 and GPR43, to regulate the metabolism and cell fate \[[@R16]\]. Dietary supplementation of butyrate has been shown to prevent high-fat diet-induced obesity and insulin resistance in mice \[[@R17]-[@R19]\] or non-alcoholic fatty liver disease in rats \[[@R20]\], through a mechanism related to promotion of energy expenditure and induction of mitochondrial function. In these studies, butyrate was administered together with the high-fat diet for prolonged periods during the induction of disease models to demonstrate its preventive actions. However, the efficacy of butyrate in the treatment of obesity and insulin resistance in established obese model was only lightly mentioned in one study without further mechanistic analysis \[[@R19]\].

Adiponectin is an adipocyte-derived cytokine with a prominent function in improving insulin sensitivity \[[@R21], [@R22]\], via targeting on mitochondrial functions \[[@R23], [@R24]\]. The anti-obesity and insulin-sensitizing actions of adiponectin are mediated by its receptors occurring in two isoforms, adipoR1 and adipoR2 \[[@R25]\]. The down-stream signaling of adiponectin receptors involves activation of 5′-adenosine monophosphate-activated protein kinase (AMPK) \[[@R26]\] and peroxisome proliferator-activated receptor-α (PPARα) \[[@R27]\], which subsequently induces mitochondria biogenesis and enhances fatty acid oxidation \[[@R28]\]. Nevertheless, it has not been explored whether adiponectin-mediated pathway is involved in the anti-obesity action of butyrate.

Thus, here we test our hypothesis that adiponectin-mediated pathway contributes to the therapeutic effects of butyrate on a high-fat diet-induced obese mouse model. We show that a short-term oral administration of sodium butyrate was able to alleviate obesity and increase insulin sensitivity through promotion of skeletal muscle mitochondrial function and fatty acid oxidation. Furthermore, we provide evidences that HDAC1 inhibition and histone hyperacetylation on the promoter of genes encoding adiponectin receptors and uncoupling proteins may contribute to butyrate activity.

RESULTS {#s2}
=======

Sodium butyrate reduces body weight gain and improves glucose tolerance {#s2_1}
-----------------------------------------------------------------------

The obese mouse model was established 8 weeks after feeding the high-fat diet, with significantly (*P* \< 0.05) higher body weight compared to the mice fed control diet (Figure [1A, 1B](#F1){ref-type="fig"}). Five gavage doses of SB alleviated glucose intolerance (Figure [1C, 1D](#F1){ref-type="fig"}). The body weight and the epididymal fat mass were significantly (*P* \< 0.05) reduced in HFB group compared to HF group (Table [2](#T2){ref-type="table"}).

###### The primer of genes for RT-PCR, mtDNA copy number, and ChIP analysis

  Primer names      Sequences                Used for
  ----------------- ------------------------ ---------------------
  COX1              ATGTTCTATCAATGGGAGC      mRNA quantification
                    TCTGAGTAGCGTCGTGGT       
  COX2              AGACGAAATCAACAACCC       mRNA quantification
                    GGAAGTTCTATTGGCAGA       mtDNA copy number
  COX3              CGAAACCACATAAATCAAG      mRNA quantification
                    AGTAGGCAAACAATAAGGA      
  ND1               CACTATTCGGAGCTTTACG      mRNA quantification
                    TGTTTCTGCTAGGGTTGA       
  ND2               ACAACCCATCCCTCACTC       mRNA quantification
                    ATTTTGGTAAGAATCCTGTT     
  ND3               CCTAACGCTAATTCTAGTTG     mRNA quantification
                    GACGTGCAGAGCTTGTAG       
  ND4               TCCTCAGTTAGCCACATAGCA    mRNA quantification
                    AGGCAGAATAGGAGTGATGATG   
  ND4L              CTATCACTTCTAGGGACACTT    mRNA quantification
                    TAGGGCTAGTCCTACAGC       
  ND5               ATAACCGCATCGGAGACA       mRNA quantification
                    TGGTAGTCATGGGTGGAG       
  ND6               ACAAAGATCACCCAGCTA       mRNA quantification
                    GGAGTTATGTTGGAAGGA       
  ATP6              AACCTGGTGAACTACGAC       mRNA quantification
                    GATGTTACTGTTGCTTGAT      
  ATP8              ATGCCACAACTAGATACAT      mRNA quantification
                    TAGTGATTTTGGTGAAGG       
  CYTB              CTGTTCGCAGTCATAGCC       mRNA quantification
                    AAGAATCGGGTCAAGGTG       
  PGC-1α            ACACCGCAATTCTCCCTTGT     mRNA quantification
                    CGGCGCTCTTCAATTGCTTT     
  UCP2              ATCTGGTCATTGTGTTAGGT     mRNA quantification
                    GGTCTCTGCTATGCTGTT       
  UCP3              ACACTTCCTCCTGCTCTC       mRNA quantification
                    AGTCCATTCTGTCCTTCCA      
  CPT-1b            CAACACTACACGCATCCC       mRNA quantification
                    CACTCTACCCTTCCTCCTG      
  Leptin receptor   TGTAAACTGGGACATAGAG      mRNA quantification
                    AGGGGTTCTTAGGTAATG       
  AdipoR1           GCTGAAAGACAACGACTACC     mRNA quantification
                    GTCAAGATTCCCAGAAAGAG     
  AdipoR2           GTGTTTTCTTGGTCGTCG       mRNA quantification
                    TGCGTCTGGCTGCTGATA       
  PPARa             GGGTGGTTGAATCGTGAG       mRNA quantification
                    CTTCTCCTTGCCTTTTGC       
  PPIA              GCAAGACCAGCAAGAAGA       mRNA quantification
                    CAGTGAGAGCAGAGATTACA     mtDNA copy number
  AdipoR1           TTCCATACATAGCATACCAG     ChIP
                    CATCCTATCTCAGCCTTT       
  AdipoR2           GAATAGCAGCACTTTTGG       ChIP
                    CGGGCTTTCAGTATGTCT       
  UCP2              CGGGGCTAAGGAGGATAA       ChIP
                    CCTCAGCGAGATAATGGC       
  UCP3              CAAGCCTAAGGGGTAAAG       ChIP
                    ACAAATTGGGCATGTCGT       

###### Body, liver, gastrocnemius muscle and epididymal fat weight

  Parameters                                                    Control (*n* = 8)   HF (*n* = 8)    HFB (*n* = 8)
  ------------------------------------------------------------- ------------------- --------------- ---------------
  Initial body weight[^1^](#tfn_001){ref-type="table-fn"} (g)   23.65 ± 0.47c       31.72 ± 0.62a   31.35 ± 0.80a
  Final body weight[^2^](#tfn_002){ref-type="table-fn"} (g)     23.20 ± 0.53c       32.46 ± 0.50a   28.35 ± 0.58b
  Liver weight (g)                                              1.10 ± 0.03b        1.24 ± 0.03a    1.08 ± 0.04b
  Gastrocnemius muscle weight (g)                               0.29 ± 0.01b        0.35 ± 0.01a    0.32 ± 0.02ab
  Epididymal fat weight (g)                                     0.43 ± 0.04c        1.33 ± 0.13a    0.81 ± 0.08b
  Liver index                                                   4.76 ± 0.13a        3.84 ± 0.10b    3.83 ± 0.13b
  Gastrocnemius muscle index                                    1.26 ± 0.08a        1.07 ± 0.04b    1.13 ± 0.06ab
  Epididymal fat index                                          1.83 ± 0.15c        4.06 ± 0.37a    2.83 ± 0.22b

Body weight before SB treatment

Body weight after SB treatment.

Data are means ± SEM.

Mean values not sharing the same letters are significantly different, *P* \< 0.05.

HF, high-fat diet; HFB, high-fat diet gavaged with sodium butyrate.

![Sodium butyrate reduces body weight gain and improves glucose tolerance\
**A.** Phenotype of C57BL/6 mice. **B.** Changes in body weight in C57BL/6 mice during 8 weeks' high-fat diet feeding. **C.** Mean blood glucose levels following GTT (*n* = 8). **D.** Area under the glucose-time curve (AUC). Control: normal control diet, HF: high fat diet, HFB: high fat diet gavage with Sodium Butyrate. The results were expressed as means ± SEM, \* indicates the differences compared to the control and \# indicates the differences between HF and HFB. Mean values not sharing the same letters are significantly different, *P* \< 0.05.](oncotarget-07-56071-g001){#F1}

Sodium butyrate restores plasma level of insulin and leptin and reduces lipid deposition in the muscle {#s2_2}
------------------------------------------------------------------------------------------------------

Plasma concentration of glucose, insulin and leptin was significantly (*P* \< 0.05) elevated in HF group, which was completely restored to control levels by SB treatment. Plasma levels of Tch and HDL-c were significantly (*P* \< 0.05) higher in HF group, which remained high after SB treatment. Plasma concentrations of TG, LDL-c and NEFA were not affected by high-fat diet or SB treatment (Table [3](#T3){ref-type="table"}). Muscle content of TG and Tch was significantly higher (*P* \< 0.05) in HF mice, which was significantly (*P* \< 0.05) reduced by SB treatment (Table [4](#T4){ref-type="table"}).

###### The biochemical and hormone parameters in plasma

  Parameters        Control (*n* = 8)   HF (*n* = 8)    HFB (*n* = 8)
  ----------------- ------------------- --------------- ---------------
  GLU (mmol/L)      12.36 ± 0.59b       14.69 ± 0.59a   11.43 ± 0.53b
  TG (mmol/L)       0.20 ± 0.04         0.27 ± 0.02     0.24 ± 0.02
  Tch (mmol/L)      2.51 ± 0.13b        3.16 ± 0.06a    3.22 ± 0.10a
  HDLc (mmol/L)     1.72 ± 0.11b        2.42 ± 0.06a    2.41 ± 0.11a
  LDLc (mmol/L)     0.52 ± 0.05         0.45 ± 0.02     0.50 ± 0.03
  NEFA (μmol/L)     858.4 ± 30.09       824.6 ± 68.19   887.4 ± 44.22
  Insulin (ng/mL)   1.51 ± 0.17b        2.39 ± 0.30a    1.25 ± 0.09b
  Leptin (ng/mL)    1.45 ± 0.19b        3.71 ± 0.62a    1.50 ± 0.26b

Data are means ± SEM.

Mean values not sharing the same letters are significantly different, *P* \< 0.05.

HF, high-fat diet; HFB, high-fat diet gavaged with sodium butyrate; GLU, glucose; TG, triglyceride; Tch, total cholesterol; LDLc, LDL-cholesterol; HDL-C, HDL-cholesterol; NEFA, non-esterified fatty acid.

###### The triglyceride, total cholesterol and ATP, AMP, ADP concentrations in gastrocnemius muscle

  Parameters      Control (*n* = 8)   HF (*n* = 8)    HFB (*n* = 8)
  --------------- ------------------- --------------- ---------------
  TG (ng/mg)      7.30 ± 1.28a        16.34 ± 2.88b   10.34 ± 0.98c
  Tch (ng/mg)     1.49 ± 0.26a        3.32 ± 0.59b    2.10 ± 0.20c
  ATP (ng/mg)     3.14 ± 0.53a        4.45 ± 0.30ab   5.36 ± 0.50b
  ADP (ng/mg)     1.03 ± 0.13a        1.52 ± 0.10a    2.02 ± 0.24b
  AMP (ng/mg)     0.31 ± 0.01a        0.33 ± 0.01a    0.42 ± 0.05b
  Energy charge   0.80 ± 0.01         0.83 ± 0.01     0.82 ± 0.01

Data are means ± SEM.

Mean values not sharing the same letters are significantly different, *P* \< 0.05.

HF, high-fat diet; HFB, high-fat diet gavaged with sodium butyrate; TG, triglyceride; Tch, total cholesterol; ATP, adenosine 5′-triphosphate; ADP, adenosine 5′-diphosphate; AMP, adenosine 5′-phosphate; Energy charge = (\[ATP\] +1/2\[ADP\])/(\[ATP\] + \[ADP\] + \[AMP\]).

Sodium butyrate improves mitochondrial function and fatty acid β-oxidation {#s2_3}
--------------------------------------------------------------------------

Although myofiber types were not affected (data not shown), muscle content of ADP and AMP was significantly (*P* \< 0.05) increased, and that of ATP was numerically increased in SB-treated obese mice, as compared to Con and HF counterparts (Table [4](#T4){ref-type="table"}). The reduced muscle lipid content in HFB group was associated with a significant (*P* \< 0.05) up-regulation of mRNA expression for hormone sensitive lipase (*Hsl*) and lipoprotein lipase (*Lpl*) (Figure [2A](#F2){ref-type="fig"}). Moreover, key genes involved in mitochondrial thermogenesis and fatty acid β-oxidation, such as uncoupling protein 2 (UCP2), uncoupling protein 3 (UCP3), carnitine palmitoyl transferase Ib (CPT-1b) and PGC1α, were all increased significantly (*P* \< 0.05) at both mRNA (Figure [2B](#F2){ref-type="fig"}) and protein levels (Figure [2C, 2D](#F2){ref-type="fig"}). Furthermore, although mtDNA copy number was not affected (data not shown), 12 out of 13 mtDNA-encoded genes (Figure [2E](#F2){ref-type="fig"}) involved in oxidative phosphorylation (OXPHOS), as well as COX4 protein (Figure [2F](#F2){ref-type="fig"}) were significantly (*P* \< 0.05) up-regulated in the HFB group compared to control and HF groups.

![Sodium butyrate improves mitochondrial function and fatty acid β-oxidation\
**A.** The mRNA expression of *Hsl* and *Lpl* in gastrocnemius muscle (*n* = 10). **B.** The mRNA expression of key genes involved in mitochondrial thermogenesis and fatty acid β-oxidation in gastrocnemius muscle (*n* = 10). **C.**, **D.** The protein expression of key genes involved in mitochondrial thermogenesis and fatty acid β-oxidation in gastrocnemius muscle (*n* = 6). **E.** The mRNA expression of mtDNA-encoded genes involved in oxidative phosphorylation (OXPHOS) in gastrocnemius muscle (*n* = 10). **F.** The protein expression of COX4 in gastrocnemius muscle (*n* = 6). The results were expressed as means ± SEM. Mean values not sharing the same letters are significantly different, *P* \< 0.05.](oncotarget-07-56071-g002){#F2}

Sodium butyrate activates adiponectin signaling pathway {#s2_4}
-------------------------------------------------------

SB treatment significantly (*P* \< 0.05) increased the mRNA expression of *Leptin receptor* (Figure [3A](#F3){ref-type="fig"}), yet the protein content was not altered (Figure [3B](#F3){ref-type="fig"}). In contrast, adipoR1 and adipoR2 were significantly (*P* \< 0.05) increased after SB treatment at both mRNA (Figure [3C](#F3){ref-type="fig"}) and protein levels (Figure [3D](#F3){ref-type="fig"}), although adiponectin content in the plasma (Figure [3E](#F3){ref-type="fig"}) and gastrocnemius muscle (Figure [3F](#F3){ref-type="fig"}) did not change. Accordantly, the two main down-stream signaling pathways of adiponectin receptors, PPARα and AMPK, were activated. PPARα was up-regulated at the level of mRNA (Figure [3G](#F3){ref-type="fig"}), but not the protein (Figure [3H](#F3){ref-type="fig"}). SB treatment significantly (*P* \< 0.05) increased the protein content of phosphorylated AMPK (p-AMPK), leading to enhanced ratio of p-AMPK/AMPK (Figure [3I](#F3){ref-type="fig"}).

![Sodium butyrate activates adiponectin signal pathway in gastrocnemius muscle\
**A.** The mRNA expression of *Leptin receptor* in gastrocnemius muscle (*n* = 10). **B.** The protein expression of leptin rectpor in gastrocnemius muscle (*n* = 6). **C.** The mRNA expression of *Adipor1* and *Adipor2* in gastrocnemius muscle (*n* = 10). **D.** The protein expression of adiponectin rectpors in gastrocnemius muscle (*n* = 6). **E.** The protein expression of adiponectin in plasma (*n* = 6). **F.** The protein expression of adiponectin in gastrocnemius muscle (*n* = 6). **G.** The mRNA expression of *Ppara* in gastrocnemius muscle (*n* = 10). **H.** The protein expression of PPARa in gastrocnemius muscle (*n* = 6). **I.** The protein expression of p-AMPK in gastrocnemius muscle (*n* = 6); Control: normal control diet, HF: high fat diet, HFB: high fat diet gavage with Sodium Butyrate. The results were expressed as means ± SEM, Mean values not sharing the same letters are significantly different, *P* \< 0.05.](oncotarget-07-56071-g003){#F3}

Sodium butyrate suppresses HDAC1 expression and modifies histone acetylation {#s2_5}
----------------------------------------------------------------------------

Butyrate acts as a histone deacetylase (HDAC) inhibitor or through binding to its G protein-coupled receptors, GPR41 and GPR43. The protein content of GPR43 and GPR41 in gastrocnemius muscle was not affected by either high-fat diet or SB treatment (Figure [4A, 4B](#F4){ref-type="fig"}). However, the expression of HDAC1 was significantly (*P* \< 0.05) decreased in HFB group (Figure. [4C](#F4){ref-type="fig"}). Furthermore, ChIP analysis detected significant increase of H3K9Ac, a hallmark of gene activation, on the promoter of *Adipor1*, *Adipor2*, *Ucp2* and *Ucp3* genes (Figure [4D](#F4){ref-type="fig"}).

![Sodium butyrate suppresses HDAC1 expression and modifies histone acetylation\
**A.** The protein expression of GPR41 in gastrocnemius muscle (*n* = 6). **B.** The protein expression of GPR43 in gastrocnemius muscle (*n* = 6). **C.** The protein expression of HDAC1 in gastrocnemius muscle (*n* = 6). **D.** Chromatin immunoprecipitation (ChIP) analyses of histone modifications on the gene promoter of *Adipor1, Adipor2, Ucp2 and Ucp3* (*n* = 4). Control: normal control diet, HF: high fat diet, HFB: high fat diet gavage with Sodium Butyrate. The results were expressed as means ± SEM. Mean values not sharing the same letters are significantly different, *P* \< 0.05.](oncotarget-07-56071-g004){#F4}

DISCUSSION {#s3}
==========

Butyrate has been reported to protect animals from high-fat diet-induced obesity and insulin resistance \[[@R17]-[@R19], [@R29]-[@R31]\]. Here, we provide the evidence that short-term oral administration (5 gavage doses in 10 days) of SB is effective in the treatment of HF diet-induced obesity and glucose intolerance, in a different experimental setting. In previous studies, butyrate was administered during the induction of disease models to demonstrate its preventive functions. The efficacy of butyrate in the treatment of established obesity and insulin resistance was lightly mentioned only in one of these studies in which a 5-week dietary butyrate supplementation was shown effective \[[@R19]\]. Several factors may contribute to the disparities in the effective dose and duration of SB administration. Firstly, compared to long-term dietary supplementation of butyrate (5 g·kg^-1^·day^-1^) in other studies \[[@R17]-[@R19], [@R29]\], 5 gavage doses of SB at 80 mg per mice in this study may ensure higher bioavailability. Secondly, in this study 3-week-old male C57BL/6J mice were fed HF diet for 8 weeks to induce obesity, whereas in other studies, older mice (4-8 weeks of age) were used and obesity was induced by feeding high-fat diet for longer period (9-12 weeks) \[[@R17]-[@R19], [@R29]\]. Therefore, compared to the severe obese model in other studies, the model established in this study may resemble a mild obesity or prediabetes condition, which is commonly seen in human society and clinical situations.

The mechanism of butyrate action for obesity and insulin resistance is related to promotion of energy expenditure and induction of mitochondrial function. AMPK and PGC-1α have been suggested to mediate the effects of butyrate to increase fatty acid β-oxidation and enhance mitochondrial uncoupling \[[@R17], [@R19]\]. In agreement with these previous publications, we also detected significant activation of AMPK and PGC-1α, in association with up-regulated expression of genes involved in lipolysis, fatty acid β-oxidation, mitochondria OXPHOS and mitochondria uncoupling after a short-term oral SB treatment in a HF diet-induced mouse model.

In this study, obesity and glucose intolerance were evident after 8-weeks feeding with high-fat diet, which is indicated by significantly increased body weight, elevated fasting blood glucose level, higher plasma leptin and insulin concentrations, as well as diminished oral glucose tolerance. Mice fed high-fat diet were reported to show significantly decreased expression of mitochondrial biogenesis genes \[[@R8]\] and impaired mitochondrial function and β-oxidation activities in skeletal muscle \[[@R7], [@R9], [@R32]\]. Also, high-fat diet fed mice exhibit inhibition of glucose uptake through inactivated AMPK signaling pathways in skeletal muscle \[[@R33]\]. Surprisingly, however, the expression of genes involved in lipolysis, β-oxidation, mitochondrial OXPHOS or mitochondria uncoupling was not altered in obese mice compared to their lean counterparts in this study. It is speculated that, compared to other tissues such as adipose tissue and liver, skeletal muscles are less vulnerable to the influence of high-fat diet in a condition of mild obesity. Nevertheless, it may not be true because muscle lipid contents including TG and Tch were significantly higher in obese mice compared to the control. Therefore, genes responsible for lipid synthesis and transport may be modulated in obese mice. However, this is beyond the scope of this study that was aimed to explore the up-stream signaling pathway of butyrate function.

The most striking effect of SB in this study is to restore the plasma leptin and insulin to control levels. Obviously this attributes to the potential actions of butyrate on adipose tissue and pancreatic β cells that secrete leptin and insulin, respectively. Certainly possible modulation of the clearance or turnover cannot be excluded. However, this study was focused on skeletal muscle, an important target of these hormones. To our disappointment, no consistent responses to SB treatment were detected for insulin receptor (data not shown) or leptin receptor that changed only at the level of mRNA. Unexpectedly, however, both adiponectin receptors, adipoR1 and adipoR2, were found to be up-regulated after SB treatment, at both mRNA and protein levels. Although both leptin and adiponectin are secreted from adipose tissue, the two adipokines behave differently in high-fat diet-induced obesity. Obese mice had significantly elevated plasma leptin level that was completely restored by SB treatment, whereas adiponectin concentration in the plasma and skeletal muscle was not altered in obese mice or affected by SB treatment. This observation implicates different regulatory mechanisms for the secretion and action of leptin and adiponectin, in response to high-fat diet and SB treatment.

The down-stream signaling of adiponectin receptors has been well documented. In this study, activation of AMPK appears to be the main pathway responsible for the beneficial effects of SB on obesity and insulin resistance. However, how SB induces activation of adiponectin receptors has not been elucidated. Several studies have addressed the transcriptional regulation of Adipor1 and Adipor2 genes. Nuclear inhibitory protein (NIP) \[[@R34]\] and activating transcription factor 3 (ATF3) \[[@R35]\] are reported to repress the promoter activity of Adipor1 gene, whereas PPARG agonist, growth hormone and SIRT1-Foxo1 signaling are shown to stimulate the promoter activity of Adipor2 gene \[[@R36], [@R37]\].

To understand how sodium butyrate up-regulates the expression of adiponectin receptors, we explored both mechanisms known to mediate butyrate action, inhibition of HDAC \[[@R15]\] and activation of GPR41 and GPR43 \[[@R16]\]. It appears that SB exerts its function in this study mainly as an HDAC inhibitor, as neither GPR41 nor GPR43 was modulated by butyrate treatment. It has been shown that butyrate prevents inhibition of promoter activity by suppression of histone deacetylase \[[@R19]\]. In this study, H3K9Ac, a gene activation mark, was found to be highly enriched in the promoter of Adipor1, Adipor2, Ucp2 and Ucp3 genes that are up-regulated by SB treatment. Certainly, the coincidence and the association analysis of all the events observed in the present study are not adequate to draw a comprehensive picture of the signaling pathway underlying butyrate action. A more detailed mechanistic study using loss of function and gain of function strategies is required to delineate the cause and consequences. Also, skeletal muscle is not a sole target for sodium butyrate when administered systematically. The actions of sodium butyrate and the underlying mechanisms in other target tissues could be very different and it merits future investigations how different tissues respond in concert to butyrate to achieve the general beneficial effects on obesity and glucose intolerance.

In summary, this study provides a better understanding of the signaling pathways through which butyrate alleviates obesity and improves glucose tolerance in a high-fat diet-induced obese mouse model. The fact that a short-term oral administration of SB is effective in alleviate diet-induced mild obesity in mice may encourage future investigation of butyrate and its derivatives in the treatment and prevention of obesity-related metabolic disorders in humans.

MATERIALS AND METHODS {#s4}
=====================

Animal models and experimental protocols {#s4_1}
----------------------------------------

Thirty six male specific pathogen-free (SPF) C57BL/6J (3-week-old, 8-10 g) mice were obtained from the Comparative Medicine Center of Yangzhou University (Yangzhou, China, certificate of quality is SCXK (Su) 2012-0004) and fed in the Laboratory Animal Center of Jiangsu Province Integrative Medicine Hospital. The mice were housed in a controlled environment (22 ± 3°C, 50-60% relative humidity) with a 12L:12D lighting cycle and allowed to adapt to their environment for one week. Then mice were randomly assigned to two groups; one was fed a control diet (Con, *n* = 12) and another was fed a high-fat diet (HF, 45% energy from fat, *n* = 24) for 8 weeks to establish obesity. The mice were fed ad libitum with free access to water and weighed once per week. HF-induced obese mice maintained on HF diet were divided into two groups (*n* = 12); HFB group was gavaged with 80 mg sodium butyrate (SB) in 1 ml deionized water per mice every other day for 10 days, while the HF group received vehicle. Mice in the control group were kept continually on a normal diet for the whole experiment. The mice were fasted overnight before sampling. The blood and gastrocnemius muscle samples were collected and stored at −80°C. All the procedures were approved by the Animal Ethics Committee of Nanjing Agricultural University, with the project number 2012CB124703. The slaughter and sampling procedures complied with the "Guidelines on Ethical Treatment of Experimental Animals'' (2006) No. 398 set by the Ministry of Science and Technology, China.

Glucose tolerance test {#s4_2}
----------------------

Eight mice from each group were used for the glucose tolerance test. They were fasted for 10 h (from 8:30 am till 18:30 pm), and were injected intraperitoneally with 2.5 g/kg glucose (G7021; Sigma). The blood glucose levels before glucose injection (0 min) and 15, 30, 60, 90, and 120 min after glucose injection were determined.

Plasma concentration of biochemical parameters and hormones {#s4_3}
-----------------------------------------------------------

Plasma concentration of glucose (GLU), triglycerides (TG), total cholesterol (Tch), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c) and non-esterified fatty acid (NEFA) was detected with automatic biochemical analyzer (Hitachi 7020; HITACHI) using commercial assay kits (995-18311, 995-33093, 999-33493, 998-09011, 993-39993 and 995-09901, respectively; Wako Pure Chemical Industries, Ltd. Wako). Plasma concentration of insulin (no.96-416) and leptin (no.96-421) were measured by China Biomarker Service, Luminex 200 (no. CNBMSLX200) using Magnetic Bead MAPmate (Merck & Millipore, Darmstadt, Germany) according to the instruction provided by the manufacturer.

Content of triglycerides and total cholesterol in gastrocnemius muscle {#s4_4}
----------------------------------------------------------------------

Muscle content of TG (E1013; Applygen Technologies, Inc.) and Tch (E1015; Applygen Technologies, Inc.) was measured using respective commercial assay kits following the manufacturer\'s instruction.

ATP, ADP and AMP levels in gastrocnemius muscle {#s4_5}
-----------------------------------------------

Muscle content of ATP, ADP and AMP was determined by high performance liquid chromatography (HPLC) according to previous publications with some modifications \[[@R38], [@R39]\]. Tissue extracts were prepared from frozen muscle using 0.6 mol/l perchloric acid, and the extracts were centrifuged at 10,000×g for 10 min at 4°C. The ATP (FLAAS), ADP (A5285) and AMP (01930) standards were purchased from Sigma. HPLC was performed with A reverse-phase column (99603, C18, 5 mm, 25064.6 mm, Dikma Technologies Inc.). The column temperature was set at 25°C. For metabolites measurements, a mobile phase consisting of 215 mmol/l KH~2~PO~4~, 1.2 mmol/l tetrabutylammonium bisulfate, 1% acetonitrile (pH 6.0) was used and the flow rate was maintained at 1.0 ml·min^-1^ by a HPLC pump (600E, Waters). Eluted samples were detected at 254 nm with a dual λ absorbance detector (2478, Waters). Calibration curves were prepared by a six-point standard (0.2, 0.1, 0.05, 0.0125 and 0.00625 mg·ml^-1^) of ATP, ADP and AMP in 0.6 mol/l perchloric acid, respectively.

Determination of mtDNA copy number {#s4_6}
----------------------------------

Total genomic DNA was isolated from muscle samples and the mtDNA copy number was determined using real-time PCR. For DNA extraction, muscle samples were incubated in a lysis buffer containing 0.5 mmol/l of EDTA, pH 8.0 and 2 mg/ml of proteinase K (Amresco, USA) at 37°C overnight. Primers specific for the control region of mitochondrial DNA (mtDNA) were used for the quantification of mtDNA, whereas primers specific for the nuclear gene peptidylprolyl isomerase A (*Ppia*) were used for standardization. Relative mtDNA copy number was calculated with 2^-ΔΔCt^ method \[[@R40]\].

RNA isolation and quantitative real-time PCR {#s4_7}
--------------------------------------------

Total RNA was extracted from frozen gastrocnemius muscle samples (40 mg) using TRIzol reagent (15596026, Invitrogen) according to the manufacturer\'s protocol. Two micrograms of RNA were used to generate cDNA by PrimeScript^®^ 1st Strand cDNA Synthesis Kit (D6110A, Takara). *Ppia* was used as an internal control. The resulting cDNA was diluted 1:25 and 2 μL of diluted cDNA was used as template in PCR reactions on a real-time PCR system (Mx3000P, Stratagene, USA). All primers were synthesized by Generay Biotech and listed in Table [1](#T1){ref-type="table"}. The 2^-ΔΔCt^ method was used to analyze real-time PCR data \[[@R40]\].

Western blotting {#s4_8}
----------------

Total protein was extracted from 40 mg frozen gastrocnemius muscle samples as previously described \[[@R41]\]. Protein concentration was measured with a Pierce BCA Protein Assay kit (23225; Thermo Scientific). Antibodies and their sources are: Adiponectin (BS6961, Bioworld), AdipoR1 (BS6797, Bioworld), AdipoR2 (14361-1-AP, Proteintech), AMPKα112 (BS1009, Bioworld), p-AMPKα1/2 (sc-33524, Santa Cruz), PGC-1α (sc-13067, Santa Cruz), UCP3 (BS2849, Bioworld), UCP2 (BS2917, Bioworld), GPR43 (sc-32906, Santa Cruz), GPR41 (sc-98332, Santa Cruz), CPT-1b (sc-20670, Santa Cruz), COX4 (MB0102, Bioworld), HDAC1 (BS6485, Bioworld), GAPDH (AP0063, Bioworld), β-actin (AP0063, Bioworld). The phosphorylated AMPK was normalized by the total AMPK.

Chromatin immunoprecipitation assay {#s4_9}
-----------------------------------

Approximately 200 mg of frozen muscle samples were homogenized in liquid nitrogen and resuspended in PBS containing protease inhibitor cocktail (no. 11697498001; Roche). Cross-linking of protein and DNA was performed by adding formaldehyde to a final concentration of 1%, and then the reaction was stopped with 2.5mol/l glycine at room temperature. The reaction mix was centrifuged and the pellets were rinsed with PBS and homogenized in a SDS lysis buffer containing protease inhibitors. Crude chromatin preparations were sonicated on ice to yield DNA fragments of 200 to 500 bp in length and pre-cleared with salmon sperm DNA-treated protein G agarose beads (40 μL, 50% slurry, sc-2003; Santa Cruz). The mixture of pre-cleared chromatin preparations and 2 μg of primary antibody (H3 lysine 9 acetylation, ab4441, Abcam) were incubated overnight at 4°C. A negative control was included with normal IgG. Protein G agarose beads (40 μl, 50% slurry, sc-2003; Santa Cruz) were added to capture the immunoprecipitated chromatin complexes. Finally, DNA fragments were released from the immunoprecipitated complexes by reverse cross-linking at 65°C for 1 h, and quantitative real-time PCR was used to quantify the fragments of target gene promoters with specific primers (see supplementary Table 1) using purified immunoprecipitated DNA as the template.

Statistical analysis {#s4_10}
--------------------

All data are presented as mean ± SEM. One-way ANOVA with a Bonferroni post hoc test was used to evaluate the statistical significance of differences among 3 groups. A value *P* \< 0.05 was considered statistically significant.
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